This week an FDA report, “Advances in FDA’s Safety Program for Marketed Drugs”, has highlighted the resources, both time and money, that the agency are dedicating to drugs that are on the market and available to the American public.
“Advances in FDA’s Safety Program for Marketed Drugs” details the new tools they have in place to ensure that once a drug is released no harm is caused to patients through side effects and negative reactions. The report shows the same amount of money is spent on post marketed drugs as pre-approval drugs. This is a response to previous suggestions that the FDA is inadequate at monitoring drug safety once a drug is on the market.
The FDA claims innovative tools such as Sentinel enable them to be ahead of the game when it comes to reporting, monitoring, analysing and reacting to issues raised.